Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1974 2
1975 4
1976 7
1977 2
1978 8
1979 5
1980 7
1981 12
1982 12
1983 10
1984 12
1985 16
1986 12
1987 14
1988 10
1989 12
1990 9
1991 17
1992 12
1993 16
1994 24
1995 25
1996 20
1997 30
1998 16
1999 17
2000 13
2001 20
2002 20
2003 31
2004 23
2005 29
2006 21
2007 27
2008 35
2009 41
2010 43
2011 31
2012 39
2013 32
2014 53
2015 47
2016 35
2017 41
2018 44
2019 35
2020 53
2021 44
2022 34
2023 36
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

1,055 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Lung Soft Tissue Neoplasm"
Page 1
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial.
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. de Bono JS, et al. Lancet Oncol. 2021 Sep;22(9):1250-1264. doi: 10.1016/S1470-2045(21)00376-4. Epub 2021 Aug 10. Lancet Oncol. 2021. PMID: 34388386 Free article. Clinical Trial.
The primary endpoint was assessed in patients who received study drug, had measurable soft-tissue disease, and had a gene alteration in one of the predefined DDR-HRR genes. ...The favourable benefit-risk profile supports the study of talazoparib in larger, random …
The primary endpoint was assessed in patients who received study drug, had measurable soft-tissue disease, and had a gene alte …
Ridaforolimus.
[No authors listed] [No authors listed] Drugs R D. 2010;10(3):165-78. doi: 10.2165/11586010-000000000-00000. Drugs R D. 2010. PMID: 20945947 Free PMC article. Review.
Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of soft-tissue and bone sarcomas. It is in phase III development for sarcoma in the EU and US, and phase II for breast cancer, endometrial cancer, non …
Both intravenous and oral formulations of the compound are being tested in clinical trials for the treatment of soft-tissue …
Liposarcoma.
Springfield D. Springfield D. Clin Orthop Relat Res. 1993 Apr;(289):50-7. Clin Orthop Relat Res. 1993. PMID: 8472432 Review.
Liposarcoma is second in frequency only to malignant fibrous histiocytoma among the soft-tissue sarcomas. It occurs almost exclusively in adults and is found most often in the thigh or retroperitoneum. ...Currently, no evidence exists that adjuvant chemotherapy is i …
Liposarcoma is second in frequency only to malignant fibrous histiocytoma among the soft-tissue sarcomas. It occurs almost exc …
Docetaxel.
Cortes JE, Pazdur R. Cortes JE, et al. J Clin Oncol. 1995 Oct;13(10):2643-55. doi: 10.1200/JCO.1995.13.10.2643. J Clin Oncol. 1995. PMID: 7595719 Review.
PURPOSE: We reviewed the preclinical and clinical profiles of the antineoplastic taxoid docetaxel (Taxotere, Rhone-Poulenc Rorer, Collegeville, PA). ...Preliminary phase II results confirmed docetaxel's activity against breast, non-small-cell and small-cell lung, ov …
PURPOSE: We reviewed the preclinical and clinical profiles of the antineoplastic taxoid docetaxel (Taxotere, Rhone-Poulenc Rorer, Col …
Eribulin in Cancer Treatment.
Swami U, Shah U, Goel S. Swami U, et al. Mar Drugs. 2015 Aug 7;13(8):5016-58. doi: 10.3390/md13085016. Mar Drugs. 2015. PMID: 26262627 Free PMC article. Review.
Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cell lung cancer. Phase I and II studies in multiple cancers and various combinations are currently ongoing. This article reviews the av …
Phase III studies have either been completed or are currently ongoing in breast cancer, soft tissue sarcoma, and non-small cel …
Role of Nectin‑4 protein in cancer (Review).
Liu Y, Han X, Li L, Zhang Y, Huang X, Li G, Xu C, Yin M, Zhou P, Shi F, Liu X, Zhang Y, Wang G. Liu Y, et al. Int J Oncol. 2021 Nov;59(5):93. doi: 10.3892/ijo.2021.5273. Epub 2021 Oct 19. Int J Oncol. 2021. PMID: 34664682 Review.
In contrast to enrichment of Nectins 1-3 in normal tissues, Nectin-4 is particularly overexpressed in a number of tumor types, including breast, lung, urothelial, colorectal, pancreatic and ovarian cancer. Moreover, the upregulation of Nectin-4 is an independent biomarker …
In contrast to enrichment of Nectins 1-3 in normal tissues, Nectin-4 is particularly overexpressed in a number of tumor types, including bre …
The Impact of Pazopanib on the Cardiovascular System.
Justice CN, Derbala MH, Baich TM, Kempton AN, Guo AS, Ho TH, Smith SA. Justice CN, et al. J Cardiovasc Pharmacol Ther. 2018 Sep;23(5):387-398. doi: 10.1177/1074248418769612. Epub 2018 Apr 29. J Cardiovasc Pharmacol Ther. 2018. PMID: 29706106 Free PMC article. Review.
Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. However, its clinical efficacy is limited by its cardiovascular side effects. ...In this review, we provide a comprehensive overview …
Pazopanib is an approved treatment for renal cell carcinoma and a second-line treatment for nonadipocytic soft-tissue sarcoma. …
Extramedullary Waldenström macroglobulinemia.
Banwait R, Aljawai Y, Cappuccio J, McDiarmid S, Morgan EA, Leblebjian H, Roccaro AM, Laubach J, Castillo JJ, Paba-Prada C, Treon S, Redd R, Weller E, Ghobrial IM. Banwait R, et al. Am J Hematol. 2015 Feb;90(2):100-4. doi: 10.1002/ajh.23880. Epub 2014 Nov 19. Am J Hematol. 2015. PMID: 25349134 Free article.
Nine (21%) patients presented with involvement at WM diagnosis, while 34 (79%) developed EMD post-therapy for WM. Most frequent EMD sites involved were pulmonary (30%), soft tissue (21%), cerebrospinal fluid (23%), renal (8%), and bone (9%). The median overall survi …
Nine (21%) patients presented with involvement at WM diagnosis, while 34 (79%) developed EMD post-therapy for WM. Most frequent EMD sites in …
Radiotherapy reimagined: Integrating nanomedicines into radiotherapy clinical trials.
DuRoss AN, Phan J, Lazar AJ, Walker JM, Guimaraes AR, Baas C, Krishnan S, Thomas CR Jr, Sun C, Bagley AF. DuRoss AN, et al. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023 May-Jun;15(3):e1867. doi: 10.1002/wnan.1867. Epub 2022 Oct 28. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023. PMID: 36308008 Review.
Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lung, esophagus, pancreas, prostate, and soft tissue sarcoma. Supported by decades of preclinical investigation and recent …
Radioenhancing nanoparticles (NPs) are being evaluated in ongoing clinical trials for various cancers including head and neck, lun …
Imaging and Surgical Treatment of Primary Pulmonary Artery Sarcoma.
Wyler von Ballmoos MC, Chan EY, Reardon MJ. Wyler von Ballmoos MC, et al. Int J Cardiovasc Imaging. 2019 Aug;35(8):1429-1433. doi: 10.1007/s10554-018-1489-8. Epub 2018 Dec 8. Int J Cardiovasc Imaging. 2019. PMID: 30535656 Review.
CT imaging also is part of routing imaging and remains as the most pertinent imaging modality to evaluate the lung parenchyma and presence of metastatic disease. Here we review the pertinent imaging modalities and tissue characteristics that facilitate recognition o …
CT imaging also is part of routing imaging and remains as the most pertinent imaging modality to evaluate the lung parenchyma and pre …
1,055 results